Description Update of the 2009 started Continuous Assessment of molecular diagnostics from the end user perspective. Hospital and private laboratories have systematically been surveyed to collect information on number of labs testing, NA tests, test volumes, used platforms (separated for amplification, hybridization, detection) and reagents.
For data reliability and accurate projections at segment level a 3 step methodology has been applied: Step 1: Identification of the total number of labs Step 2: Identification of the total number of laboratories using NA technologies (in several lab units per hospital)
Step 3: Interviews with NA laboratories on NA test volume, kits, platforms and trends. A list of 39 NA tests has been provided to the labs for structured data entry.
The report covers key platforms of molecular diagnostics, including Polymerase Chain Reaction (PCR), Real Time PCR (RT-PCR), Traditional and Next Generation Sequencing, TMA, LCR, NASBA, SDA, HCA, bDNA.
Executive Summary dii is an international market research company entirely specialised in healthcare providing market information and support to strategic business decisions. In cooperation with key industry we have desigend the Continuous Molecular Market Assessment which has been realized in 2009, 2012, 2014 and 2016 , 2014 and 2016 with the 2 main objectives:
1) Assess market sizes and market shares for molecular diagnostics (# of labs using which technology, test volumes, platforms and reagents)
2) Understand long term trends and needs
Format of deliverables Excel - detailed data reports with extrapolation of # of labs, test volumes, market shares for platforms and reagents per country & test
Our reports have been used by over 10K customers, including:
2020 will be remembered for the COVID-19 pandemic, masks, social distancing protocol, alternate care sites, Moderna, Pfizer, BioNTech, AstraZeneca, RT-PCR, and serology testing (or all the above). However, in the midst of our response to the global pandemic, remarkable advancements were made in another great frontier in medicine that remains...
Report Scope: The scope of this report is broad and covers the components available in the polymerase chain reaction (PCR) for point-of-care (POC) diagnostics market and potential end-users. Revenue forecasts from 2020 to 2025 are given for types of kits and equipment, with estimated value derived from the revenues of manufacturers. The...
The global veterinary diagnostics market grew at a CAGR of around 7% during 2014-2019. Veterinary diagnostics refer to various tests conducted to detect the presence of disorders among animals. They are conducted by analyzing the samples of blood, feces and tissues of livestock, wild and pet animals. These tests are...
The nucleic acid amplification, detection, and diagnostics market was valued at US$ 14,014.59 million in 2019 and is projected to reach US$ 38,162.68 million by 2027; it is expected to grow at a CAGR of 13.4% during 2020–2027. The growth of the nucleic acid amplification, detection, and diagnostics market is mainly attributed to the factors...
KEY FINDINGS The North America precision medicine market is projected to evolve with a CAGR of 9.67%, over the forecast years of 2021 to 2028. The region’s key market growth drivers include the rising focus of well-established diagnostics manufacturers to expand their portfolio in NGS-based molecular diagnostics, as well...
Summary Biocartis Group NV (Biocartis) operates as a molecular diagnostics company that provides personalized medicine for patients through its molecular diagnostics.The company undertakes the development of diagnostics technology platforms for multiplexed detection of bio-analytes, with oncology as its key focus area. Its...
Summary Mobidiag Ltd (Mobidiag) operates as a biotechnology company that develops and markets products for molecular diagnosis of infectious diseases and test kits.The company’s products portfolio includes Novodiag, Amplidiag, and Prove-it. Its Amplidiag is a diagnostic test for high-volume screening of gastrointestinal...
Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer.Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test...
Colorectal Cancer Screening Coverage
Medical Devices Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.